Overview
The purpose of this observational study is to describe the effectiveness of deucravacitinib treatment and quality of life in adults with moderate-to-severe plaque psoriasis in routine clinical practice in Germany over a 5-year period
Eligibility
Inclusion Criteria:
- Patients with a physician-reported diagnosis of moderate-to-severe plaque psoriasis initiating deucravacitinib according to approved label in the European Union
- The decision upon treatment with deucravacitinib must have been made before enrollment and independently of this non-interventional observational study
- Patient is at least 18 years of age at the time of treatment decision
- Patient provided written informed consent to participate in the study
Exclusion Criteria:
- Any contraindications according to the approved deucravacitinib Summary of Product Characteristics
- Prior treatment with deucravacitinib
- Simultaneous participation in an interventional clinical trial for moderate-to-severe psoriasis